Obinutuzumab

Red

Brand Name(s):Gazyvaro

Indication:Untreated Chronic Lymphocytic Leukaemia

Chronic lymphocytic leukaemia (CLL)
Follicular Lymphoma (FL)

Rationale:1,2

Considered:Aug-14

Review Date:Jan-26

Comments:
NICE TA663
Venetoclax plus obinutuzumab is recommended for untreated CLL in adults, only if there is a 17p deletion or TP53 mutation, or there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab, or bendamustine plus rituximab, is unsuitable.

NICE TA629 recommends Obinutuzumab with bendamustine followed by obinutuzumab maintenance, as an option for treating follicular lymphoma that has not responded or progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen. …………………………Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab- guidance (TA629)